A phase II trial of hepatic ablation of metastases to modulate and enhance immunotherapy response in non-small cell lung cancer (HAMMER-NSCLC) Journal Article

   

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1989 1988 1987 1986 1985 1984 1983 1982 1981 1980 1979 1978 1977 1976 1975 1974 1973 1972 1971 1970 1969 1968 1967 1966 1965 1964 1963 1962 1961 1960 1959 1958 1957 1956 1955 1954 1953 1952 1951 1950 1949 1948 1947 1946 1945 1944 1943 1942 1941 1940 1939 1938 1937 1936 1935 1934 1933 1932 1931 1930 1929 1928 1927 1926 1925 1924 1923 1922 1921 1920 1919 1918 1917 1916 1915 1914 1913 1912 1911 1910 1909 1908 1907 1906 1905 1904 1903 1902 1901 1900 1899 1898 1897 1896 1895 1894 1893 1892 1891 1890 1889 1888 1887 1886 1885 1884 1883 1882 1881 1880 1879 1878 1877 1876 1875 1874 1873 1872 1871 1870 1869 1868 1867 1866 1865 1864 1863 1862 1861 1860 1859 1858 1857 1856 1855 1854 1853 1852 1851 1850

Authors:	McMillan, M. T.; Reyngold, M.; Crane, C. H.; O'Brien, D. A. R.; Williams, V. M.; Zinovoy, M.; Cuaron, J. J.; Gönen, M.; Kaiser, A.; Sopka, D. M.; Gomez, D. R.; Schoenfeld, A. J.; Bott, M.; Romesser, P. B.
Article Title:	A phase II trial of hepatic ablation of metastases to modulate and enhance immunotherapy response in non-small cell lung cancer (HAMMER-NSCLC)
Abstract:	<p>BackgroundAnti-programmed cell death protein 1/programmed death-ligand 1 (anti-PD-[L]1) immunotherapy promotes systemic anti-tumor immunity through expanding neoantigen-specific CD8 + T cells, but it is less effective in patients with liver metastases. Nearly 20% of non-small cell lung cancer (NSCLC) patients develop liver metastases, and these patients are characterized by fewer and less active effector T cells. Preclinical work has shown that liver metastases cause systemic immunosuppression through siphoning neoantigen-specific CD8 + T cells from systemic circulation with subsequent macrophage-mediated intrahepatic death. In preclinical models, liver metastasis-directed radiotherapy can reverse this systemic immunosuppression and sensitize tumors to anti-PD-(L)1 therapy. However, it is unknown whether liver metastasis-directed stereotactic ablative radiotherapy (liver SABR) can sensitize tumors to anti-PD-(L)1 in human NSCLC.MethodsThe HAMMER-NSCLC trial is a randomized phase II study planned to enroll 68 patients with newly diagnosed metastatic NSCLC - without known targetable EGFR, ALK, BRAF, or ROS1 alterations - involving the liver. Patients will be randomized 1:1 to standard-of-care anti-PD-(L)1-based immunotherapy +/- platinum-based chemotherapy (Arm 1) or standard-of-care treatment plus liver SABR (Arm 2). Patients can be enrolled and randomized up to the start of cycle 3 of immunotherapy. For patients in Arm 2, it is preferred that liver SABR be completed prior to initiating standard-of-care anti-PD-(L)1 therapy. Liver SABR must be completed prior to the third cycle of anti-PD-(L)1 or within 90 days of anti-PD-(L)1 therapy initiation, whichever is sooner. The primary endpoint is progression-free survival (PFS). Secondary endpoints include the safety/tolerability of liver SABR when added to anti-PD-(L)1-based immunotherapy, overall survival, and hepatic progression. The study needs 68 patients combined in the two arms to demonstrate an improvement in PFS with a hazard ratio of 0.6 to provide 80% power with a one-sided alpha of 10%.DiscussionThe HAMMER-NSCLC trial will determine if adding liver SABR to first-line anti-PD-(L)1-based immunotherapy +/- platinum-based chemotherapy can improve median PFS in patients with NSCLC liver metastases.Trial registrationNCT05657873, registered 12/12/2022.</p>
Keywords:	clinical trial; radiotherapy; liver metastasis; non-small cell lung cancer; anti-pd-1; anti-pd-l1; sabr
Journal Title:	BMC Cancer
Volume:	25
ISSN:	1471-2407
Publisher:	Biomed Central Ltd
Date Published:	2025-09-02
Start Page:	1408
Language:	English
ACCESSION:	WOS:001562389700004
DOI:	10.1186/s12885-025-14779-5
PROVIDER:	wos
PMCID:	PMC12403433
PUBMED:	40898159
Notes:	Corresponding MSK author is Paul B. Romesser -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/229091